Sequencing-guided cHemotherapy Optimization using Real-Time Evaluation in Newly Diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA
PhasED-seq in Patients with Diffuse Large B-cell Lymphoma (DLBCL)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAU9823
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1) determine whether it is feasible to measure ctDNA in real-time during standard treatment for newly diagnosed DLBCL, and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of chemotherapy. The PhasED-seq assay has not yet been approved by the Food and Drug Administration (FDA).
Hua-Jay Cherng, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with diffuse large B-cell lymphoma (DLBCL)? Yes No
Are you pregnant or nursing? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator